114 related articles for article (PubMed ID: 29331267)
1. Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB).
Letourneau JJ; Stroke IL; Hilbert DW; Sturzenbecker LJ; Marinelli BA; Quintero JG; Sabalski J; Ma L; Diller DJ; Stein PD; Webb ML
Bioorg Med Chem Lett; 2018 Feb; 28(4):756-761. PubMed ID: 29331267
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR studies of novel benzodiazepinedione-based inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB).
Letourneau JJ; Stroke IL; Hilbert DW; Cole AG; Sturzenbecker LJ; Marinelli BA; Quintero JG; Sabalski J; Li Y; Ma L; Pechik I; Stein PD; Webb ML
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3601-3605. PubMed ID: 30392779
[TBL] [Abstract][Full Text] [Related]
3. Fidaxomicin inhibits toxin production in Clostridium difficile.
Babakhani F; Bouillaut L; Sears P; Sims C; Gomez A; Sonenshein AL
J Antimicrob Chemother; 2013 Mar; 68(3):515-22. PubMed ID: 23208832
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization and antimicrobial susceptibilities of extra-intestinal Clostridium difficile isolates.
Zheng L; Citron DM; Genheimer CW; Sigmon SF; Carman RJ; Lyerly DM; Goldstein EJ
Anaerobe; 2007; 13(3-4):114-20. PubMed ID: 17531516
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
[TBL] [Abstract][Full Text] [Related]
6. Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB.
Puri AW; Lupardus PJ; Deu E; Albrow VE; Garcia KC; Bogyo M; Shen A
Chem Biol; 2010 Nov; 17(11):1201-11. PubMed ID: 21095570
[TBL] [Abstract][Full Text] [Related]
7. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
[TBL] [Abstract][Full Text] [Related]
8. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
9. Lead Optimization Yields High Affinity Frizzled 7-Targeting Peptides That Modulate
Hansen S; Nile AH; Mehta SC; Fuhrmann J; Hannoush RN
J Med Chem; 2019 Sep; 62(17):7739-7750. PubMed ID: 31429553
[TBL] [Abstract][Full Text] [Related]
10. Dioctahedral smectite neutralization activity of Clostridium difficile and Bacteroides fragilis toxins in vitro.
Martirosian G; Rouyan G; Zalewski T; Meisel-Mikołajczyk F
Acta Microbiol Pol; 1998; 47(2):177-83. PubMed ID: 9839376
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Allosteric Triggers of Clostridium difficile Toxin B Auto-proteolysis as a Therapeutic Strategy.
Ivarsson ME; Durantie E; Huberli C; Huwiler S; Hegde C; Friedman J; Altamura F; Lu J; Verdu EF; Bercik P; Logan SM; Chen W; Leroux JC; Castagner B
Cell Chem Biol; 2019 Jan; 26(1):17-26.e13. PubMed ID: 30482680
[TBL] [Abstract][Full Text] [Related]
12. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
13. Clostridium difficile infections among Jordanian adult hospitalized patients.
Nasereddin LM; Bakri FG; Shehabi AA
Am J Infect Control; 2009 Dec; 37(10):864-6. PubMed ID: 19712999
[TBL] [Abstract][Full Text] [Related]
14. Assessment of changes in the epidemiology of Clostridium difficile isolated from diarrheal patients in Hungary.
Terhes G; Urbán E; Sóki J; Szikra L; Konkoly-Thege M; Vollain M; Nagy E
Anaerobe; 2009 Dec; 15(6):237-40. PubMed ID: 19682411
[TBL] [Abstract][Full Text] [Related]
15. Toxin A-negative, toxin B-positive Clostridium difficile.
Drudy D; Fanning S; Kyne L
Int J Infect Dis; 2007 Jan; 11(1):5-10. PubMed ID: 16857405
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antibacterial activity against Clostridium difficile of novel demethylvancomycin derivatives.
Zhang SJ; Yang Q; Xu L; Chang J; Sun X
Bioorg Med Chem Lett; 2012 Aug; 22(15):4942-5. PubMed ID: 22765891
[TBL] [Abstract][Full Text] [Related]
17. Kefir-isolated Lactococcus lactis subsp. lactis inhibits the cytotoxic effect of Clostridium difficile in vitro.
Bolla PA; Carasi P; Serradell Mde L; De Antoni GL
J Dairy Res; 2013 Feb; 80(1):96-102. PubMed ID: 23217732
[TBL] [Abstract][Full Text] [Related]
18. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
19. Toxin production of Clostridium difficile in sub-MIC of vancomycin and clindamycin alone and in combination with ceftazidime.
Zarandi ER; Mansouri S; Nakhaee N; Sarafzadeh F; Moradi M
Microb Pathog; 2017 Jun; 107():249-253. PubMed ID: 28286152
[TBL] [Abstract][Full Text] [Related]
20. Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile in vitro.
Trejo FM; Pérez PF; De Antoni GL
Antonie Van Leeuwenhoek; 2010 Jun; 98(1):19-29. PubMed ID: 20232250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
